Innovative Cancer Targeted Pro-Drugs.
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 2, 2020 | Series C | $27M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Phoenix Insurance Company | — | Series C |
Biotel | — | Series C |